Transdermal drug delivery of labetolol hydrochloride: System development, In Vitro; Ex Vivo and In Vivo characterization

Current Drug Delivery

Volumn 2, Issue 2, 2005, Pages 125-131

  Aqil, M ^a   Zafar, Saqib ^a   Ali, Asgar ^a   Ahmad, Shoaib ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Drug release; Hypertension; Labetolol; Skin permeation; Transdermal

Indexed keywords

DIMETHYL SULFOXIDE; EUDRAGIT; EUDRAGIT RL 100 PVP K 30; EUDRAGIT RS; EUDRAGIT X1; EUDRAGIT X2; EUDRAGIT X3; EUDRAGIT Y1; EUDRAGIT Y2; EUDRAGIT Y3; LABETALOL; POVIDONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; EVALUATION; EVAPORATION; EX VIVO STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SHELF LIFE; SKIN PERMEABILITY; SKIN POTENTIAL; SOLVENT EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, CUTANEOUS; ANIMALS; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; LABETALOL; MALE; PERMEABILITY; RATS; RATS, WISTAR; SKIN; SOLUBILITY;

EID: 16844379761     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567201053586038     Document Type: Article

References (25)

1. Pai, R.; Desai, M.; Babtiwale, A.; Shrivastava, A. Drug Dev. Ind. Pharm., 1994, 20, 1905-1909.
2. Valenta, C.; Almasi-Szabo, I. Drug Dev. Ind. Pharm., 1995, 21, 1799-1805.
3. Krishna, R.; Pandit, J. Drug Dev. Ind. Pharm., 1994, 20, 2459-2465.
4. Verma, P.; Iyer, S. Drug Dev. Ind. Pharm., 2000, 26, 471-476.
5. Monti, D.; Saettone, M.; Giannaccini, B.; Galli-Angeli, J. Cont. Rel., 1995, 33, 71-77.
6. Jarvinen, A.; Backstrom, A.; Elfstrom, C.; Viitanen, A. Maturitas, 2001, 38, 189-196.
7. Rafiee-Tehrani, M.; Safai-Nikui, N.; Peteriet, H.; Beckert, T. Drug Dev. Ind. Pharm., 2001, 27, 431-437.
8. Shin, S.; Lee, H. Eur. J. Pharm. Biopharm., 2002, 54, 201-206.
9. Arora, P.; Mukherjee, B. J. Pharm. Sci., 2002, 91, 2076-2089.
10. Aqil, M.; Ali, A. Eur. J. Pharm. Biopharm., 2002, 54, 161-164.
11. Aqil, M.; Sultana, Y.; Ali, A. Acta Pharm., 2003, 53, 119-126.
12. Devi, V.; Saisivam, S.; Maria, G.; Deepti, P. Drug Dev. Ind. Pharm., 2003, 29, 495-503.
13. Tipre, D.; Vavia, P. Drug Dev. Ind. Pharm., 2003, 29, 71-78.
14. Jain, S.; Chourasia, M.; Sabitha, M.; Jain, R.; Jain, A.; Ashawat, M.; Jha, A. Drug Deliv., 2003, 10, 169-177.
15. Dollery, C. Therapeutic Drugs. Churchill Livingstone Inc.: New York, 1991.
16. Zafar, S.; Ali, A.; Aqil, M., The AAPS Journal, Manuscript # 1577 (Under review).
17. The United States Pharmacopoeia, 23rd ed., US Pharmacopoeial Convention Inc.: Rockville, MD, 1999.
18. Aqil, M.; Sultana, Y.; Ali, A.; Dubey, K.; Najmi, A.K.; Pillai, K. K. Drug Deliv., 2004, 11, 27-31.
19. Bonina, F.P.; Carellii, V.; Cols, G.D.; Montenegro, L.; Nannipieri, E. Int. J. Pharm., 1993, 100, 41-47.
20. Monograph on 'labetolol hydrochloride' In: Indian Pharmacopoeia, New Delhi, 1996, pp. 425-426.
21. Ralph, J.R. In: Handbook of Hypertension de Jong W Ed., Elsevier Science B.V.: Amsterdem, New York, Oxford, 1984, Vol.4. pp. 287-295.
22. Makaritisis, K.P.; Johns, G.G.; Gavras, I.; Gavras, H.; Hypertension. 2000, 35, 609-613.
23. Arranz, C.; Tomat, A.; Fellet, A.; Garria, J.; Bolaszak, A.M.; Costa, M.A. Nephron physiology, 2003, 95, 36-42.
24. Muir, K.; Hidalgo, I. J. Chromatography, 1984, 305, 222-227.
25. ICH stability guidelines (No. QIA (R2), published in Federal Register, Vol. 68, No. 225, Nov. 2003, pp. 65717-18.